作者：
Hudie,Wei [1]
;
Haiyan,Cai [1]
;
Yuhao,Jin [2]
;
Pilin,Wang [2]
;
Qingqing,Zhang [2]
;
Yihui,Lin [3]
;
Weixiao,Wang [4]
;
Jinke,Cheng [5]
;
Naiyan,Zeng [1]
;
Ting,Xu [2]
;
Aiwu,Zhou [1]
作者单位：
Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of The Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
[1]
The Therapeutic Antibody Research Center of SEU-Alphamab, Southeast University, Nanjing, China.
[2]
Division of Translational Medicine, 3D Medicines Corporation, Shanghai, China.
[3]
Department of Pharmaceutical Engineering, College of Humanities-Information, Changchun University of Technology, Changchun, China.
[4]
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
[5]
DOI
10.18632/oncotarget.17558
PMID
28881627
发布时间
2018-11-13
换一批
换一批
